

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



WUXI APPTEC CO., LTD.*
無錫藥明康德新藥開發股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2359)

SUPPLEMENTAL ANNOUNCEMENT
CONNECTED TRANSACTION
PURCHASE OF SERIES A SHARES IN D3 BIO

Reference is made to the announcement of WuXi AppTec Co., Ltd.* (無錫藥明康德新藥開發股份有限公司) (the “**Company**”) dated November 17, 2020 (the “**Announcement**”) in relation to, among other things, the purchase of Series A-1 Shares in D3 Bio by WuXi Fund I. Unless otherwise defined, capitalized terms used in this announcement shall have the same meanings as those defined in the Announcement.

This announcement is made to provide supplemental information on the Other Series A Investors, namely Matrix Partners VI, Elbrus Investments and ASL, notwithstanding the fact that the Company does not have the right under the Share Purchase Agreement to have access to the identities and particular information of the ultimate beneficial owners of these investors.

Matrix Partners VI is a company incorporated in Hong Kong and is 90% owned by Matrix Partners China VI, L.P., which is an exempted limited partnership organized and existing under the laws of the Cayman Islands. The general partner of Matrix Partners China VI, L.P. is Matrix China Management VI, L.P.. The general partner of Matrix China Management VI, L.P. is Matrix China VI GP GP, Ltd.

Elbrus Investments is an indirect wholly-owned subsidiary of Temasek. Temasek is wholly owned by the Singapore Minister for Finance, which is a body corporate under the Singapore Minister for Finance (Incorporation) Act (Chapter 183). As a commercial investment company, Temasek has its own board of directors and a professional management team. Temasek owns and manages its portfolio with full commercial discretion and flexibility under the guidance of its board of directors. The Singapore government is not involved in Temasek's investment, divestment, or any other business or operational decisions. According to its official website, the net portfolio value of Temasek is reportedly S\$306 billion as at March 31, 2020. It has invested in Hong Kong listed companies including Ocumension Therapeutics (stock code: 1477) and JHBP (CY) Holdings Limited (stock code: 6998).

ASL is managed by Boyu Capital, a fund. Boyu Capital has invested in Hong Kong listed companies including Hansoh Pharmaceutical Group Company Limited (stock code: 3692), CStone Pharmaceuticals (stock code: 2616), New Century Healthcare Holding Co. Limited (stock code: 1518) and Antengene Corporation Limited (stock code: 6996).

Save as disclosed above, all other information as set out in the Announcement remain unchanged and shall continue to be valid for all purposes. This announcement is supplemental to and should be read in conjunction with the Announcement.

By order of the Board
WuXi AppTec Co., Ltd.*
Dr. Ge Li
Chairman

Hong Kong, December 3, 2020

As at the date of this announcement, the Board comprises Dr. Ge Li, Mr. Edward Hu, Dr. Steve Qing Yang, Mr. Zhaohui Zhang and Dr. Ning Zhao as executive Directors, Mr. Xiaomeng Tong and Dr. Yibing Wu as non-executive Directors and Dr. Jiangnan Cai, Ms. Yan Liu, Mr. Dai Feng, Dr. Hetong Lou and Mr. Xiaotong Zhang as independent non-executive Directors.

* *For identification purposes only*